Title Physician

HR+HER2- Breast Cancer

NCT ID : 04895761
Protocol Number : IMV P2100-SUR-S11
Phase : 1
Location : Saint John's Cancer Institute
Parvin Peddi, M.D.

Known Metastatic Breast Cancer with ER-Positive and HER2-Negative Primary Lesions

NCT ID : 05068726
Protocol Number : GE-280-401
Phase : 4
Location : Saint John's Cancer Institute
Parvin Peddi, M.D.

Biomarker Low Risk Node Positive Breast Cancer: TAILOR RT.

NCT ID : 03488693
Protocol Number : CCTGMA.39
Phase : 3
Location : Santa Monica, CA
Janie Grumley, M.D.

Locally Advanced or Metastatic HR+/HER2- Breast Cancer

NCT ID : 04851613
Protocol Number : LAE205INT3101
Phase : Phase Ib/II
Location : Saint John's Cancer Institute
Parvin Peddi, M.D.

Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer

NCT ID : 04958785
Protocol Number : GS-US-586-6144
Phase : 2
Location : Saint John's Cancer Institute
Parvin Peddi, M.D.

THE COMPASSHER2 TRIALS (COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2-POSITIVE BREAST CANCER): COMPASSHER2 Residual Disease (RD), A Double-Blinded, PHASE III Randomized Trial Of T-DM1 And Placebo Compared With T-DM1 And TUCATINIB

NCT ID : 04457596
Protocol Number : A011801
Phase : Phase III
Location : Saint John's Cancer Institute
Parvin Peddi, M.D.

Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases (SWOG)

NCT ID : 04647916
Protocol Number : S2007
Phase : 2
Location : Saint John's Cancer Institute
Parvin Peddi, M.D.